Centene Corporation Company Profile (NYSE:CNC)

Centene Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNC."

Centene Corporation (NYSE:CNC) announced its quarterly earnings data on Tuesday, July, 26th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.20. The business earned $10.90 billion during the quarter, compared to analyst estimates of $10.80 billion. Centene Corporation had a net margin of 1.57% and a return on equity of 14.19%. The company's revenue was up 97.9% on a year-over-year basis. During the same period last year, the firm posted $0.72 EPS. View Centene Corporation's Earnings History.

Centene Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Centene Corporation.

18 brokers have issued 12 month price targets for Centene Corporation's stock. Their predictions range from $64.00 to $95.00. On average, they expect Centene Corporation's stock price to reach $82.31 in the next year. View Analyst Ratings for Centene Corporation.

Here are some recent quotes from research analysts about Centene Corporation stock:

• 1. According to Zacks Investment Research, "Centene has seen substantial inorganic growth in the last five years. The acquisition of Health Net in 2016 which boosted the company’s growth, expansion and asset base, is worth a mention here. This apart, its solid financial position provides a major boost to its capital deployment initiatives. The company’s strong Managed care segment also impresses. Well evident of all these tailwinds, year to date, the stock rallied 44%, outpacing 210% gain of the Zacks HMO industry. The company’s strong and consistent performance is likely to have generated confidence among the investors. However, the company rigorously suffers from continuously rising level of debt that result in increasing borrowing cost which again keeps draining the bottom line. In addition, steep increase in acquisition related expenses as well as the regulatory uncertainty from the change of presidency are major concerns." (7/10/2017)
• 2. Cantor Fitzgerald analysts commented, "This morning, CNC reported 1Q17 results. Revenue of $11.7 billion was slightly ahead of FactSet consensus. Adjusted EPS was $1.12 vs. our estimate." (4/25/2017)
• 3. Leerink Swann analysts commented, "We reiterate our Market Perform rating on CNC while raising PT to $64 from $62 after the 4Q report and almost 6% move up yesterday." (2/9/2017)

Some companies that are related to Centene Corporation include Incyte Corporation (INCY), Zimmer Biomet Holdings (ZBH), Illumina (ILMN), Astellas Pharma (ALPMY), Edwards Lifesciences Corporation (EW), Cardinal Health (CAH), C.R. Bard (BCR), Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Lonza Group Ag (LZAGY), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN), Eisai Co., Ltd (ESALY), Smith & Nephew SNATS (SNN), Quest Diagnostics Incorporated (DGX) and IDEXX Laboratories (IDXX).

Centene Corporation's management team includes the folowing people:

• Michael F. Neidorff, Chairman of the Board, President, Chief Executive Officer
• Jeffrey A. Schwaneke CPA, Chief Financial Officer, Executive Vice President, Treasurer
• Keith H. Williamson, Executive Vice President, General Counsel, Secretary
• Christopher D. Bowers, Executive Vice President - Marketing
• Cynthia J. Brinkley, Executive Vice President - Global Corporate Development
• Jesse N. Hunter, Executive Vice President - Products
• Christopher R. Isaak, Senior Vice President, Corporate Controller and Chief Accounting Officer
• Mark J. Brooks, Senior Vice President, Chief Information Officer
• Christopher A. Koster, Senior Vice President - Corporate Services
• Orlando Ayala, Independent Director

Centene Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vaughan Nelson Investment Management L.P. (0.34%), Bank of Montreal Can (0.22%), First Quadrant L P CA (0.21%), BB&T Corp (0.12%), National Pension Service (0.10%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Centene Corporation stock include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Institutional Ownership Trends for Centene Corporation.

Centene Corporation's stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., APG Asset Management N.V., Osborne Partners Capital Management LLC, Vaughan Nelson Investment Management L.P., Handelsbanken Fonder AB, Independent Portfolio Consultants Inc., BB&T Corp and NN Investment Partners Holdings N.V.. Company insiders that have sold Centene Corporation stock in the last year include Carol Goldman, Christopher D Bowers, Jeffrey A Schwaneke, Jesse N Hunter, Keith H Williamson, Kenneth Rone Baldwin, Mark J Brooks, Michael F Neidorff, Richard A Gephardt and Robert K Ditmore. View Insider Buying and Selling for Centene Corporation.

Centene Corporation's stock was bought by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Bank of Montreal Can, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Meeder Asset Management Inc., Mn Services Vermogensbeheer B.V., National Pension Service, Bank of The West and Polianta Ltd. View Insider Buying and Selling for Centene Corporation.

Shares of Centene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Centene Corporation stock can currently be purchased for approximately $84.20.